When was CureMatch founded?

CureMatch was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is CureMatch located?

CureMatch is headquartered in San Diego, United States.

How many employees does CureMatch have?

As of Aug 31, 2026, the latest employee count at CureMatch is 25.

Is CureMatch a funded company?

CureMatch is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 01, 2015.

When was the latest funding round of CureMatch?

CureMatch's latest funding was a $***** Seed round on Aug 15, 2017, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.25B in funding in 2026 to date.

Where does CureMatch rank among its competitors?

CureMatch ranks 132nd amongst 569 active competitors, of which 171 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of CureMatch?

CureMatch's top competitors include Exact Sciences, MedGenome and GRAIL. Among them, GRAIL secured the most recent funding round in June, 2026.

CureMatch - 2026 Company Profile, Team, Funding & Competitors

Company Details

Precision oncology: AI-powered treatment matching for personalized cancer care. This digital health company focuses on personalized medicine and combination therapy in oncology. Their Decision Support System guides oncologists in selecting customized cancer drugs based on individual patient molecular tumor profiles. The platform enables oncologists to become experts in personalized medicine by providing actionable intelligence towards advanced cancer treatment options. They leverage proprietary algorithms and extensive curation of genomic data to rank genomically matched combination treatments. The goal is to provide clear, accessible, predictive treatment analysis, equipping oncologists with actionable knowledge tailored for each unique case. This supports personalized combination therapy, improves patient outcomes, and facilitates wider adoption of precision treatment options. The offering includes molecular profiling, genomic analysis, and ranked drug therapies, utilizing AI and knowledge representation for precision medicine support.

Key Metrics

Founded Year

2015

Location

San Diego, United States

Stage

Seed

Latest Funding Round

Seed, Aug 15, 2017, $*****

Investors

Serra Ventures & 2 more

Ranked

132^nd among 569 active competitors

Employee Count

25 as on Aug 31, 2026

Similar Companies

Exact Sciences & 779 more

View CureMatch's full profile

CureMatch has raised funding over 2 rounds. Its first funding round was on Oct 01, 2015. Its latest funding round was a Seed round on Aug 15, 2017 for $*****. 1 investor participated in its latest round. CureMatch has 3 institutional investors.

Here is the list of recent funding rounds of CureMatch:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 15, 2017	7835534	Seed	3610577	4277609	1282777	3253162
Oct 01, 2015	1722608	Seed	6515405	6959117	1752703	Analytics Ventures

Access funding benchmarks and valuations. Sign up today!

View details of CureMatch's funding rounds and investors

The founders of CureMatch is Razelle Kurzrock.

Here are the details of CureMatch's key team members:

Razelle Kurzrock: Co-Founder & CMO of CureMatch.
Contact Info: 1 email address
Stephane Richard: CEO of CureMatch.
Contact Info: 1 email address

View details of CureMatch's Founder profiles and Board Members

CureMatch's employee count trend

CureMatch has 25 employees as of Aug 26. Here is CureMatch's employee count trend over the years:

Uncover CureMatch's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CureMatch include Exact Sciences, MedGenome and GRAIL. Here is the list of Top 10 competitors of CureMatch, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
2nd	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
3rd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
4th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
5th	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	67/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
7th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
8th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
9th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
10th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
132nd	CureMatch 2015, San Diego (United States), Seed	Precision oncology: AI-powered treatment matching for personalized cancer care	-	Serra Ventures, Analytics Ventures & 1 others	41/100